Drugs / 3,4-methylenedioxymethamphetamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07494214 | Mar 2026 → Mar 2027 expected | — | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4-methylenedioxymethamphetamine | “Preliminary evidence from case series and small clinical trials suggests that 3,4-methylenedioxymethamphetamine (MDMA) may be promising candidates for the treatment of chronic...” NCT07494214 ↗ |
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07494214 ↗ |